Supporting the

Neuroendocrine Cancer Community

Great News for our European Friends

Oct 4, 2017

The European Commission (EC) has approved the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

Read more here:–gep-net–tumours.php


We have to be next!!